SCHEMBL21296467

SCHEMBL21296467

CSc1nc(O)cc(N2CCC(C)(NC(=O)O)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 1/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
RXFP1 Q9HBX9 1/20 0.42
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 4/20 0.33
PTGER4 P35408 3/20 0.33
MEN1 O00255 2/20 0.33
TSHR P16473 1/20 0.33
HPGD P15428 2/20 0.33
PTPN11 Q06124 2/20 0.33
HSD17B10 Q99714 1/20 0.33
HTT P42858 2/20 0.32
RAB9A P51151 1/20 0.32
ATM Q13315 1/20 0.32
TP53 P04637 2/20 0.32
GAA P10253 1/20 0.32
RET P07949 1/20 0.32
POLB P06746 1/20 0.30
ALOX12 P18054 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22791979 0.84 RET (0.41) FFAR4KDM4EMAPTRXFP1KMT2A
SCHEMBL5148961 0.68 KDM4E (0.51) KDM4ERXFP1ALDH1A1TP53GAA
SCHEMBL21115092 0.68 HDAC3 (0.41) PTPN11RETHDAC3HDAC4HDAC1
SCHEMBL23309826 0.67 PTPN11 (0.73) PTPN11
SCHEMBL16915565 0.66 HDAC3 (0.48) PTPN11HDAC3HDAC4HDAC1HDAC7
SCHEMBL16915590 0.66 HDAC3 (0.46) PTPN11HDAC3HDAC4HDAC1HDAC7
SCHEMBL20153234 0.65 KMT2A (0.58) KDM4EMAPTRXFP1KMT2AALDH1A1
SCHEMBL20264603 0.64 ABL1 (0.39) KMT2APTGER4PTPN11RETHDAC3
SCHEMBL21989767 0.64 BTK (0.47) RETHDAC3HDAC4HDAC1HDAC7
SCHEMBL16915559 0.63 PTPN11 (0.48) PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3755699-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF Relay Therapeutics, Inc. (US) 2020-12-30 EP disclosed
US-20200392161-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF SCHRÖDINGER, INC. 2020-12-17 US disclosed
WO-2019165073-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200392161-A1 SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF PTPRCAP, PTPRJ, PTPRC FFAR4 3801/4885KDM4E 1021/4885MAPT 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.